Abstract

Introduction. Hypertension is one of the most common risk factors of cardiovascular disease, which remains the major cause of death in Poland. Number of patients with controlled hypertension remains low. The aim of the study was to evaluate strategies of hypotensive pharmacotherapy, to determine prevalence of poorly controlled hypertension and of cardiovascular risk factors and comorbidities in these patients. Material and methods. Non-interventional, observational study was conducted in patients treated in various outpatient care settings. The study had two stages: 1) screening, with collection of baseline medical data in 50 patients with hypertension attending one physician; 2) collection of additional medical data concerning 10 patients with poorly controlled hypertension. Results. The total of 42,338 patients was included in the screening stage, and of those 54.3% had poorly controlled hypertension. In the latter group, the most prevalent cardiovascular risk factor was dyslipidemia (77.8%) and abdominal obesity (68.3%). More than 25% respondents were smokers. Ischaemic heart disease and diabetes were the most common comorbidities (33.4% and 31%, respectively). As to pharmacotherapy, 73% of patients received more than one antihypertensive agent (angiotensin converting enzyme inhibitor 59.7%, beta-blocker 45%, and diuretic 38.7%), and 10.6% subjects were treated with fixed dose combinations. In 38 patients antihypertensive therapy was modified more than a year before. Conclusions. Of all hypertensive patients in outpatient care setting, still more than half do not reach the target blood pressure values. In this group, the most common risk factors and comorbidities are dyslipidemias, obesity, ischaemic heart disease and diabetes. Nearly three-quarters of patients receive more than one hypotensive agent (usually angiotensin-converting enzyme inhibitor, beta-blocker, and diuretic). Antihypertensive therapy was not modified for more than six months in over 60% of patients.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call